News
CERS
2.600
+0.39%
0.010
Weekly Report: what happened at CERS last week (0615-0619)?
Weekly Report · 2d ago
Cerus showcases INTERCEPT Blood System evidence at ISBT Congress
PUBT · 06/17 12:30
Weekly Report: what happened at CERS last week (0608-0612)?
Weekly Report · 06/15 09:39
Cerus director Eric Bjerkholt disposes of 20,454 common shares worth $53,180.40
PUBT · 06/12 01:17
Cathie Wood Sells Robinhood Stock, Doubles Down On This George Soros-Backed AI Stock
Benzinga · 06/11 02:43
Cerus amends credit facilities, expands term loan capacity
TipRanks · 06/08 21:40
Cerus closes debt facility up to $110M
TipRanks · 06/08 12:45
CERUS - ENTERS NEW 5-YEAR REVOLVING LOAN AGREEMENT UP TO $45 MLN
Reuters · 06/08 12:31
Cerus closes new debt facility with MidCap Financial for up to $110 million
PUBT · 06/08 12:30
Weekly Report: what happened at CERS last week (0601-0605)?
Weekly Report · 06/08 09:37
Cerus Corporation Closes New Debt Facility of Up to $110 Million
Barchart · 06/08 07:30
Cerus Shareholders Approve Equity Plan Expansion and Governance
TipRanks · 06/03 21:33
Cerus shareholders approve amended 2024 equity incentive plan, adding 10 million shares
PUBT · 06/03 20:19
Cerus COO Vivek K. Jayaraman sells 16,667 shares for $50,001 under 10b5-1 plan
PUBT · 06/02 23:46
Weekly Report: what happened at CERS last week (0525-0529)?
Weekly Report · 06/01 09:39
*Radoff Criticizes Cerus Increase of Shrs Available for Grant of Equity Awards to Executives and Directors
Dow Jones · 05/27 16:55
BRADLEY L. RADOFF: ANNOUNCES INTENT TO WITHHOLD VOTES FROM CERUS CHAIR AND CEO WILLIAM GREENMAN AND DIRECTOR ANN LUCENA
Reuters · 05/27 15:35
Cerus shareholder Radoff urges vote withhold from CEO Greenman, compensation chair Lucena over dilution, losses
PUBT · 05/27 15:35
TD Cowen Sticks to Their Buy Rating for Cerus (CERS)
TipRanks · 05/27 14:35
Weekly Report: what happened at CERS last week (0518-0522)?
Weekly Report · 05/25 09:41
More
Webull provides a variety of real-time CERS stock news. You can receive the latest news about Cerus through multiple platforms. This information may help you make smarter investment decisions.
About CERS
Cerus Corporation is a biomedical products company. The Company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives: platelets, plasma, red blood cells and to produce INTERCEPT Fibrinogen Complex (IFC), and pathogen reduced plasma, cryoprecipitate reduced. The INTERCEPT Blood System for Cryoprecipitation uses its plasma system to produce IFC for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. In addition, the INTERCEPT Blood System for Cryoprecipitation is used to produce pathogen reduced plasma, cryoprecipitate reduced.